Solvonis Therapeutics PLC (LSE:SVNS), the biopharmaceutical company developing treatments for central nervous system disorders, is refining its strategy to prioritise advancing lead programme SVN-001 through phase III trials rather than pursuing an earlier licensing or partnering transaction.
The board has concluded that greater shareholder value may be available at or following successful completion of a final stage study than through an earlier deal, citing the relatively short time and capital required to reach that milestone.
SVN-001 targets severe alcohol use disorder (AUD), a high-burden condition with significant unmet need.
The decision follows a broader strategic review and comes against a shifting backdrop in the US biopharmaceutical market, where the White House issued an executive order in April aimed at accelerating research, regulatory review and patient access for psychedelic drugs in serious mental illness.
The board noted the FDA has already begun awarding priority vouchers to qualifying companies following that order, while share prices of several US-listed peers have risen sharply.
Strategic validation in the space has also intensified, with Japanese drugmaker Otsuka agreeing to acquire Transcend Therapeutics for up to $1.225 billion.
The board believes companies carrying clinically advanced assets through phase III in adjacent neuropsychiatric settings are attracting the strongest public-market and strategic interest, and that SVN-001 is well placed to benefit from that dynamic.
The company's transformation during 2025 underpins the revised strategy.
Solvonis completed the acquisition of Awakn Life Sciences last May, changed its name, and reshaped itself into a focused CNS business targeting addiction and psychiatry.
Alongside SVN-001, the group is advancing SVN-002, a US-focused phase II planning programme for moderate-to-severe AUD, and has expanded its pipeline with emerging assets, including SVN-114 in post-traumatic stress disorder.
An AI-enabled discovery platform has also been launched to generate novel CNS drug candidates.
Cash and cash equivalents stood at £1.72 million at year-end, which the company expects to provide funding through to the end of 2026.
The company made a £3.47 million loss, reflecting its focus on R&D.